ATE495445T1 - Verfahren und zusammensetzungen in verbindung mit morbus alzheimer - Google Patents

Verfahren und zusammensetzungen in verbindung mit morbus alzheimer

Info

Publication number
ATE495445T1
ATE495445T1 AT05788728T AT05788728T ATE495445T1 AT E495445 T1 ATE495445 T1 AT E495445T1 AT 05788728 T AT05788728 T AT 05788728T AT 05788728 T AT05788728 T AT 05788728T AT E495445 T1 ATE495445 T1 AT E495445T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
methods
compositions related
proteins
Prior art date
Application number
AT05788728T
Other languages
English (en)
Inventor
Jules Westbrook
Helen Byers
Malcolm Ward
Simon Lovestone
Abdul Hye
Stephen Lynham
Richard Joubert
Petra Prefot
Karsten Kuhn
Christian Baumann
Juergen Schaefer
Thorsten Prinz
Stefan Kienle
Original Assignee
Proteome Sciences Plc
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences Plc, King S College London filed Critical Proteome Sciences Plc
Application granted granted Critical
Publication of ATE495445T1 publication Critical patent/ATE495445T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AT05788728T 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer ATE495445T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0421639.6A GB0421639D0 (en) 2004-09-29 2004-09-29 Methods and compositions relating to alzheimer's disease
PCT/GB2005/003756 WO2006035237A2 (en) 2004-09-29 2005-09-29 Methods and compositions relating to alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE495445T1 true ATE495445T1 (de) 2011-01-15

Family

ID=33397455

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05788728T ATE495445T1 (de) 2004-09-29 2005-09-29 Verfahren und zusammensetzungen in verbindung mit morbus alzheimer

Country Status (10)

Country Link
US (2) US7897361B2 (de)
EP (3) EP1794594B1 (de)
JP (3) JP5483816B2 (de)
AT (1) ATE495445T1 (de)
AU (1) AU2005288689B2 (de)
CA (1) CA2580532C (de)
DE (1) DE602005025897D1 (de)
DK (1) DK2354795T3 (de)
GB (1) GB0421639D0 (de)
WO (1) WO2006035237A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
GB0426859D0 (en) * 2004-12-07 2005-01-12 Proteome Sciences Plc Diagnosis of neurodegenerative disorders
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
EP1937815B1 (de) 2005-09-13 2015-05-13 National Research Council of Canada Verfahren und zusammensetzungen zur modulation der tumorzellaktivität
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2344881A4 (de) * 2008-09-26 2012-03-07 Univ Melbourne Biomarker für morbus alzheimer
IT1392551B1 (it) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
DK2389587T3 (en) * 2009-01-26 2014-03-03 Electrophoretics Ltd Diagnostic and prognostic methods related Alzheimer's Disease
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
AU2010202926B2 (en) * 2009-09-11 2016-07-14 Electrophoretics Limited Markers and methods relating to the assessment of Alzheimer's disease
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP5906519B2 (ja) * 2011-09-13 2016-04-20 国立大学法人 熊本大学 二次元電気泳動による蛋白質の分離方法
HK1201328A1 (en) * 2011-11-18 2015-08-28 Alnylam Pharmaceuticals, Inc. Quantification of transthyretin and its isoforms
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
EP2831310A4 (de) 2012-03-29 2016-04-06 Univ Arizona Nanoskaliges verfahren zum erzeugen von für individuelle proteinvarianten selektiven reagenzien
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
AU2013246621A1 (en) 2012-04-13 2014-11-27 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
US9891108B2 (en) 2012-10-03 2018-02-13 The Research Foundation For The State University Of New York Spectroscopic method for Alzheimer's disease diagnosis
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
AU2014223824B2 (en) * 2013-02-28 2020-02-27 Albert Einstein College Of Medicine, Inc. Tuberculosis biomarkers and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
GB201310150D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Methods and compositions relating to alzheimer's disease
GB201310203D0 (en) 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
CA2922559A1 (en) * 2013-08-27 2015-03-05 Crc For Mental Health Ltd Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
GB201322094D0 (en) 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease
WO2015103594A1 (en) * 2014-01-06 2015-07-09 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
AU2016243516A1 (en) * 2015-03-27 2017-11-09 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US9904961B2 (en) 2015-05-07 2018-02-27 Kuwait University System and method for determining the feedback capacity of information distributed in a complex network
JP6193942B2 (ja) * 2015-09-09 2017-09-06 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN105403649B (zh) * 2015-12-01 2018-03-20 深圳大学 一种检测ad的尿液多肽组ad生物标记物
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
JP6947450B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
KR102690820B1 (ko) * 2017-07-14 2024-08-02 가부시키가이샤 엠씨비아이 질환 검출 방법
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
JP6408087B2 (ja) * 2017-07-25 2018-10-17 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN113024651A (zh) * 2019-12-25 2021-06-25 中国医学科学院药物研究所 阿尔茨海默病生物标志物及其应用
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
JP2025537481A (ja) * 2022-10-18 2025-11-18 イムヌジェネティクス アーゲー アルツハイマー型認知症に罹患している又はアルツハイマー型認知症を発症する危険性のある対象の特定
CN117831756B (zh) * 2024-03-05 2024-06-28 精智未来(广州)智能科技有限公司 一种认知障碍的辅助分析方法、装置、设备及存储介质

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20030211622A1 (en) 1998-06-29 2003-11-13 Roberts L. Jackson Methods and compositions to assess oxidative brain injury
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
JP2001249128A (ja) * 2000-03-06 2001-09-14 Ikagaku:Kk 動脈硬化症またはアルツハイマー病の診断用キット
US20020174447A1 (en) * 2001-01-23 2002-11-21 Greenspan Ralph J. Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
US6528309B2 (en) * 2001-03-19 2003-03-04 The Regents Of The University Of California Vacuum-mediated desiccation protection of cells
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
MXPA05000159A (es) * 2002-07-03 2005-09-30 Univ Illinois Reactivos y metodos para identificar y modular la expresion de genes de senescencia del tumor.
US7575929B2 (en) * 2002-10-02 2009-08-18 Dmi Life Sciences, Inc. Diagnosis of multiple sclerosis with diketopiperazines
US20060188951A1 (en) * 2003-02-24 2006-08-24 In Hee Mook Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer's disease using same
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease

Also Published As

Publication number Publication date
JP2011209291A (ja) 2011-10-20
JP2014209132A (ja) 2014-11-06
EP2354795B1 (de) 2014-12-17
EP1794594A2 (de) 2007-06-13
JP2008514946A (ja) 2008-05-08
CA2580532A1 (en) 2006-04-06
US20080070995A1 (en) 2008-03-20
EP2354795A1 (de) 2011-08-10
AU2005288689B2 (en) 2011-10-27
EP2562545A1 (de) 2013-02-27
WO2006035237A2 (en) 2006-04-06
DE602005025897D1 (de) 2011-02-24
CA2580532C (en) 2019-06-25
WO2006035237A3 (en) 2006-08-03
JP5483816B2 (ja) 2014-05-07
US20110165146A1 (en) 2011-07-07
EP1794594B1 (de) 2011-01-12
AU2005288689A1 (en) 2006-04-06
JP5893269B2 (ja) 2016-03-23
US7897361B2 (en) 2011-03-01
DK2354795T3 (en) 2015-02-16
GB0421639D0 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
ATE495445T1 (de) Verfahren und zusammensetzungen in verbindung mit morbus alzheimer
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
EA200901373A1 (ru) Аминогетероциклические соединения
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MY153979A (en) Substituted piperidino-dihydrothienopyrimidine
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
EP1758605A4 (de) Prouroguanylin als therapeutische und diagnostische mittel
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties